Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $153.7 million.

  • Ocular Therapeutix's Total Liabilities rose 782.38% to $153.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $153.7 million, marking a year-over-year increase of 782.38%. This contributed to the annual value of $153.7 million for FY2025, which is 782.38% up from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Total Liabilities is $153.7 million, which was up 782.38% from $152.7 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Total Liabilities high stood at $160.9 million for Q4 2023, and its period low was $107.3 million during Q2 2022.
  • Over the past 5 years, Ocular Therapeutix's median Total Liabilities value was $138.9 million (recorded in 2024), while the average stood at $134.8 million.
  • Examining YoY changes over the last 5 years, Ocular Therapeutix's Total Liabilities showed a top increase of 9113.94% in 2021 and a maximum decrease of 3707.85% in 2021.
  • Ocular Therapeutix's Total Liabilities (Quarter) stood at $116.9 million in 2021, then fell by 2.55% to $113.9 million in 2022, then skyrocketed by 41.28% to $160.9 million in 2023, then dropped by 11.4% to $142.6 million in 2024, then increased by 7.82% to $153.7 million in 2025.
  • Its Total Liabilities stands at $153.7 million for Q4 2025, versus $152.7 million for Q3 2025 and $145.4 million for Q2 2025.